After a slapdown on Orkambi price, Vertex is dropping French trial sites while warning patients on access
Vertex Pharma $VRTX is playing hardball with French drug regulators — and cystic fibrosis patients waiting for their next-gen triple are getting caught in the middle.
Mired in a long-running dispute over the reimbursement level for their drug Orkambi, Vertex has decided to shut out the trial sites it had selected in France for the late-stage combination studies for its cystic fibrosis drugs, including the experimental VX-659, which has raised hopes for a broad swath of patients.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters